Main characteristics of the 19 patient series found.
| Author | Country and year | Patients, n (% with liver metastases) | OS (months) | OS with no history of HM (months) | OS with history of HM (months) | Variables affecting survival |
| Perera NK | Australia 2013 | 66 (24.0) | At 5 years 39.6% | Not reported | Not reported | None |
| Kamiyoshihara M | Japan 2014 | 73 (37.0) | At 5 years 70%, 33.7 m | At 5 years 59.5%, 39.5 m | CEA level, number of metastases, female | |
| Renaud S | France 2013 | 320 (15.0) | 74 m (60–87) | 47 m (21–76) | Lymph node involvement, Liver metastases | |
| Matsui T | Japan 2013 | 186 (13.4) | At 5 years 63% | At 5 years 54%, 60 m | ||
| Javed MA | UK 2014 | 66 (39.0) | 45 m | 43 m | 33 m | ASA class, Metastasis size |
| Cho S | Korea 2013 | 84 (26.2) | 31 m | 45.1 m | 26.3 m | Age, Number of metastases, DFS, CEA |
| Iida T | Japan 2013 | 1223 (18.8) | 69.5 m | At 5 years 55.3%, 75.7 m | At 5 years 44.6% 49.4 m | Age, Number of metastases, Metastasis size |
| Hattori N | Japan 2013 | 96 (30.2) | At 5 years 61.3% | At 5 years 69% | At 5 years 43% | Lymph node involvement, Liver metastases, DFS |
| Jarabo JR | Spain 2011 | 79 (27.8) | At 5 years 53.3% | At 5 years 50.1% | At 5 years 62.5% | Age, CEA level, Lymph node involvement |
| Zabaleta J | Spain 2011 | 90 (18.7) | 84 m | 89.2 m (74.1–104.2) | 58.8 m (34.4–83.1) | DFI, Age, Lymph node involvement, Early recurrence, Metastasis size, History of liver metastases |
| Borano P | Italy 2011 | 137 (31.4) | At 5 years 55.4% | HR 0.919 | Number of metastases, DFS | |
| Chen F | Japan 2011 | 75 (25.3) | At 5 years 59.7% | Not reported | Not reported | |
| Suemitsu R | Japan 2011 | 57 (56.1) | 53.9% 65.2 m | At 5 years 71.5% | At 5 years 43.1% | TNM stage of primary tumour |
| Hwang MR | Korea 2010 | 125 (29.6) | At 5 years 58% | At 5 years 13.7% | Early recurrence, Non-pulmonary metastasis, CEA level, Lymph node involvement | |
| Landes U | Switzerland 2010 | 40 (60.0) | 87 m, at At 5 years 53.8% | 40 m At 5 years 29.2% | Liver metastasis | |
| Riquet M | France 2010 | 127 (24.4) | At 5 years 41% | At 5 years 39.2% | At 5 years 53.3% | Vascular invasion |
| Watanabe K | Japan 2009 | 122 (29.2) | At 5 years 67.8% | Not reported | Not reported | CEA level, Lymph node involvement |
| Lin BR | Taiwan 2009 | 63 (23.8) | At 5 years 43.9% | At 5 years 26.8% | At 5 years 45.9% | Surgical approach, Liver metastasis, DFS |
OS: overall survival; HM: hepatic metastasectomy; CEA: carcinoembryonic antigen; DFS: disease-free survival